These include trials of pre-publicity prophylaxis, or PrEP, which is analyzing the use of oral ARVs to lessen HIV risk in HIV harmful people. Addititionally there is one other ongoing effectiveness trial known as MTN 003, or VOICE, that is evaluating daily use of 1 percent tenofovir gel along with oral use of tenofovir or tenofovir/emtricitabine. Ongoing and additional research is needed to clarify the full potential of ARV-based avoidance.There is growing evidence that tumor cell aggregates or spheroids give a more representative style of tumors in vivo than can be achieved with conventional adherent monolayers. Such spheroids exhibit several relevant physiological traits including identical morphology, the forming of cell-cell bonds, decreased proliferation rates, increased cell survival, tumor dormancy, and a hypoxic core. Applying this model to in a 3D tradition invasion assay provides a more physiological approach for assessing tumor invasion and providing a visual component which can be quantitated through image evaluation.